Sirt1/2-IN-3 

Sirt1/2-IN-3 (compound PS9) is a dual inhibitor of SIRT1/2 with IC₅₀s of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respsectivley. Sirt1/2-IN-3 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-3 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines^[1].

IC50: 1.4 μM (SIRT1), 2.0 μM (SIRT2), 72.3 μM (SIRT3)^[1]

Sirt1/2-IN-3 (compound hsa55) (5 μM; 48 h) induces apoptosis in different tumor cells, with IC₅₀s of 6.5 μM (MV4-11), 9.2μM (MOLM-13), 27.2 μM (THP1), 17.4 μM (Jurkat), respectively^[1].Sirt1/2-IN-3 (100 μM; 30 min) decreases the thermal stability of both SIRT1 and SIRT2 proteins at different temperatures, and also (25 μM, 30 μM; 6 h) increase level of the acetylated form of p53 and α-tubulin in MOLM-13 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

363.82

C₁₇H₁₄ClNO₄S

301313-42-8

O=S(NC1=CC(Cl)=C(C2=C1C=CC=C2)O)(C3=CC=C(OC)C=C3)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cai H, et al. Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells. J Chem Inf Model. 2023 Aug 14;63(15):4780-4790.  [Content Brief]